Assessment and treatment of dementia in medical patients

Psychotherapy and Psychosomatics

Volumn 69, Issue 2, 2000, Pages 59-69

  Foy, Julia M ^a   Starr, John M ^a  

^a Royal Victoria Hospital Edinburgh   (United Kingdom)

Author keywords

Alzheimer's disease; Cholinesterase inhibitors; Cognition disorders; Dementia; Geriatric assessment

Indexed keywords

ACETYLSALICYLIC ACID; ALPRAZOLAM; ANTIDEPRESSANT AGENT; ANTIOXIDANT; BENZODIAZEPINE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CARBAMAZEPINE; CHLORPROMAZINE; CHOLINESTERASE INHIBITOR; CLOZAPINE; DONEPEZIL; ESTROGEN; LITHIUM; LORAZEPAM; NEUROLEPTIC AGENT; NONSTEROID ANTIINFLAMMATORY AGENT; OXAZEPAM; PHYSOSTIGMINE; RISPERIDONE; RIVASTIGMINE; SELEGILINE; SEROTONIN UPTAKE INHIBITOR; TACRINE; THIORIDAZINE; TRAZODONE; VENLAFAXINE;

ALZHEIMER DISEASE; BEHAVIOR DISORDER; CLINICAL TRIAL; COGNITIVE DEFECT; DEMENTIA; DISABILITY; DOSE TIME EFFECT RELATION; DRUG MECHANISM; EXTRAPYRAMIDAL SYMPTOM; FATIGUE; FUNCTIONAL ASSESSMENT; GASTROINTESTINAL SYMPTOM; GERIATRIC DISORDER; HUMAN; LIVER TOXICITY; MENTAL DISEASE; NAUSEA; PARKINSON DISEASE; PSYCHOTHERAPY; REVIEW; VISUAL IMPAIRMENT;

EID: 0033980560     PISSN: 00333190     EISSN: None     Source Type: Journal    
DOI: 10.1159/000012368     Document Type: Review

References (32)

1. Piccini C, Bracco L, Amaducci L: Treatable and reversible dementias: An update. J Neurol Sci 1998;153:172-181.
2. Kay D, Beamish P, Roth M: Old age disorders in Newcastle-upon-Tyne. Br J Psychiatry 1964; 110:146-158.
3. Kaye JA: Diagnostic challenges in dementia. Neurology 1998;51(suppl 1):S45-S52.
4. American Psychiatric Association: The Diagnostic and Statistical Manual of Psychiatric Disorders, ed 4 (DSM-IV). Washington, APA, 1994.
5. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM: Clinical diagnosis of Alzheimer's disease: Report of the NINCDS-ADRDA work group under the auspices of Department of Health and Human Services Task Force on Alzheimer's disease. Neurology 1984;34:939-944.
6. World Health Organization: International Statistical Classification of Diseases and Related Health Problems, rev 10 (ICD-10). Geneva, WHO, 1992, vol 1.
7. Chamic M: What does morbidity have to do with disability? Disabil Rehabil 1995;17:323-327.
8. World Health Organisation: International Classification of Impairments, Disabilities and Handicaps. Geneva, WHO, 1980.
9. Cummings JL, Benson DF: Dementia: A clinical approach, ed 2. Boston, Butterworths, 1992.
10. Ganguli M: The use of screening instruments for the detection of dementia. Neuroepidemiology 1997;16:271-280.
11. Robinson BE: Guidelines for the inital evaluation of the patient with memory loss. Geriatrics 1997;52:30-39.
12. Knopman DS: The inital recognition and diagnosis of dementia. Am J Med 1998;104:2S-12S.
13. Macdonald AJD: ABC of mental health - Mental health in old age. BMJ 1997;316:413-417.
14. Folstein MF, Folstein SE, McHugh PR: Mini-Mental State: A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975;12:189-198.
15. Folstein MF: Differential diagnosis of dementia. The clinical process. Psychiatr Clin North Am 1997;20:45-57.
16. Freidl W, Schmidt R, Stronegger WJ, Irmler A, Reinhart B, Koch M: Mini-Mental State Examination: Influence of sociodemographic, environmental and behavioural factors and vascular risk factors. J Clin Epidcmiol 1996;49:73-78.
17. Teng EL, Chui HC: The Modified Mini-Mental State (3Ms) Examination. J Clin Psychiatry 1987;48:314-318.
18. Geldmacher DS, Whitehouse PJ Jr: Differential diagnosis of Alzheimer's disease. Neurology 1997;48(5 suppl 6):82-89.
19. Brun A: Frontal lobe degeneration of the non-Alzheimer type revisited. Dementia 1993;4: 126-131.
20. Office of Technology Assessment Task Force: Confronting Alzheimer's disease and other dementias. Philadelphia, Lippincolt, 1988.
21. Hashinski V: Preventable senility: A call for action against the vascular dementias. Lancet 1992;340:645-647.
22. Tatemichi TK, Desmond DW, Stern Y, Sano M, Mayeux R, Andrews H: Prevalence of dementia after stroke depends on diagnostic criteria. Neurology 1992;42(suppl 3):413.
23. Clarfield AM: The reversible dementias: Do they reverse? Ann Intern Med 1988;1109:476-489.
24. Schneider LS: New therapeutic approaches to cognitive impairment. J Clin Psychiatry 1998; 59(suppl 11):8-13.
25. Watkins PB, Zimmerman HJ, Knapp MJ, Gracon SI, Lewis KW: Hepatotoxic effects of Tacrine administration in patients with Alzheimer's disease. JAMA 1994;271:992-998.
26. Rogers SL, Doody RS, Mohs RC, Friedhoff LT, the Donepezil Study Group: Donepezil improves cognition and global function in Alzheimer's disease. Arch Intern Med 1998;158: 1021-1031.
27. Smith CD, Carney JM, Starke-Reed PE, et al: Excess brain protein oxidation and enzyme dysfunction in normal aging and Alzheimer's disease: Proc Natl Acad Sci USA 1991;88: 10540-10543.
28. McBee WL, Dailey ME, Dugan E, Schumaker SA: Hormone replacement therapy and other potential treatments for dementias: Endocrinol Metab Clin North Am 1997;26:329-345.
29. Cohen G, Spina MP: Deprenyl suppresses the oxidant stress associated with increased dopamine turnover. Ann Neurol 1998;26:689-690.
30. McGeer PL, McGeer EG, Rogers J, Sibley J: Anti-inflammatory drugs and Alzheimer's disease. Lancet 1990;335:1037.
31. McGreer PL, Schulzer M, McGreer EG: Arthritis and anti-inflammatory agents as possible protective factors for Alzheimer's disease. A review of 17 epidemiologic studies. Neurology 1996;47:425-432.
32. Finkel SI: Managing the behavioural and psychological signs and symptoms of dementia. Int Clin Psychopharmacol 1997;12(suppl 4):S25-S28.